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Abstract. Pasteur cholera vaccine consists of isolated antigenic fractions from V. cholerae El Tor 
Ogawa and Inaba. Enteric coated microgranules were prepared from antigen lyophilisate. Three doses of 
this vaccine were administered orally to 19 healthy young Thai adults at one week intervals. None of the 
volunteers experienced untowards reactions. The vibriocidal antibody responses manifested a significant 
antibody rise ( >  4 fold) to serovar Inaba in 8 vaccinees (42.1%) and Ogawa in 4 (21 .I%). Five and 6 vac- 
cinees (26.3% and 31.6'%) showed a 2 4  fold rise of IgG and IgA anti-LPS, respectively. 
INTRODUCTION 
Vibrio cholerae is a non-invasive pathogen that 
does not penetrate the intestinal mucosa and some 
evidence suggests that the immunity is mediated 
by intestinal secretory IgA (sIgA) antibodies 
(Svennerholm et al, 1978; Pierce, 1978). Oral 
administration of an antigen is the most efficient 
method for eliciting intestinal secretory antibodies, 
so most current research involves the use of oral 
vaccine with either non-living antigen or  live 
attenuated vaccine strains. 
The major attraction of non-living oral vaccines 
is their safety but multiple doses are required. 
Until now two oral cholera vaccines consisting of 
kiIled V. cholerae 01 whole cells of both biovars 
and serovars, either with or without the B subunit 
of cholera toxin, have been studied (Svennerholm 
et al, 1982; 1984 a, b; Black et al, 1987; Migasena 
et al, 1989; Clemens et al, 1988). Three doses of 
1 x 10" organisms of killed whole cells (WC) plus 
1 mg of B subunit (BS) given a t  two week intervals 
elicited 33% and 42% significant rise of vibriocidal 
antibodies to Inaba and Ogawa, respectively (Mi- 
gasena et at, 1989). A field trial in Bangladesh 
recently showed that three doses of 1 x 10" organ- 
isms of killed WC and 1 mg of BS given at  four 
week intervals provided 85%, 62% protection 
during the first six months and one year of follow 
up respectively (Clemens et al, 1988). 
Another candidate oral cholera vaccine is the 
Pasteur vaccine. It consists of isolated antigenic 
fractions from V. cholerae El Tor Ogawa and 
Inaba (Dodin and Wiart, 1975). It was shown that 
extracts of Vibrio cholerae given to rabbits by the 
oral route could induce a strong antibody response 
in both serum and intestinal fluid (Dodin and 
Wiart, 1975). This vaccine was tried during a n  epi- 
demic of cholera in Zaire and was claimed to have 
96% efficacy (Dodin et al, 1984), but the study 
design was not quite optimal. Other studies were 
carried out  suggesting that the vaccine induced 
both serum vibriocidal titers and intestinal pro- 
duction of antigen specific IgA (Langevin-Perriat 
et al, 1988). With these promising findings, it was 
considered appropriate to evaluate its safety and 
immunogenicity in volunteers in Thailand where 
cholera is endemic. 
MATERIALS AND METHODS 
Volunteers 
Participants in this study were healthy young 
Thai adults aged 20-40 years from the Bangkok 
area who passed the medical and psychological 
screening and gave informed, signed consent. NO 
volunteers had a history of cholera vaccination 
for the past five years. 
Vaccines 
Pasteur oral cholera vaccine consisted of isolated 
antigenic fractions from V. cholerae El Tor Ogawa 
and Inaba. The component includes a complex of 
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smooth type lipopolysaccharide and outer mem- 
brane proteins. Enteric coated microgranules 
were prepared from antigen lyophilisate. Each 
capsule contains 370 mg of enteric coated micro- 
granules which comprises 30 mg of lyophilisate 
corresponding to 3 mg of the antigenic fraction. 
Immunization schedule 
All volunteers received three oral doses at one 
week intervals. Volunteers fasted for two hours 
and 90 minutes prior to and post vaccination. 
Immune response 
Sera were collected from volunteers before and 
7,14 and 21 days after the first dose of vaccination. 
Jejunal fluid was collected by aspiration before 
and 21 days after the first dose of vaccine. 
For sera, vibriocidal antibody was measured 
by a microtechnique (Beneson et a/, 1968). Antibody 
to Vibrio cholerae LPS was assayed by ELISA 
(Svennerholm el al, 1984 a, b). 
For jejunal fluid, specific sIgA antibodies to 
LPS of Vibrio cholerae were measured by ELISA 
(Svennerholm et al, 1984 a, b; Young et al, 
1980). 
RESULTS 
Nineteen volunteers, 15 males and 4 females 
with mean age of 24.5 years (ranged from 20 to 34 
years) were studied. The mean weight was 56 kg, 
with a range of 5Ck62.5 kg. There were no adverse 
effects observed after any dose of vaccine. 
Table 1 showed that the serum antibody levels 
before vaccination were low and the responses to 
vaccination were only modest. The detected rise is 
sIgA in jejunal fluid was due to a response in one 
volunteer. 
The distribution of antibody responses in 
serum and in jejunal fluid are shown in Table 2. 
After three oral doses of Pasteur vaccine, 8 
(42.1%) and 4 (21.1%) developed 2 four-fold rise 
of vibriocidal antibody to Inaba and Ogawa, 
respectively. With respect to anti-LPS antibody, 5 
(26.3%) and 6 (3 1.5%) developed > four fold rise 
of serum IgG and IgA antibodies. 
parable with those after oral killed whole cell& 
subunit vaccine reported from our previous studies 
(Migasena et al, 1989) (Table 3). 
DISCUSSION 
This study confirmed that Pasteur vaccine was 
safe, easily administered and caused no side effects 
in Thai adults. Similar results were obtained from 
the other ethnic population (Langevin-Perriat et 
al, 1988). The seroversion in terms of vibriocidal 
antibody was comparable between whole cell& 
subunit vaccine and Pasteur vaccine (Migasena et 
al, 1989). However the peak GMT of anti-Inaba 
vibriocidal antibody with Pasteur vaccine in this 
study was higher than that with the WC-BS vaccine; 
on the other hand, with the anti-Ogawa antibody, 
the killed whole cell-B subunit was better. Even it 
is not certain that protection against cholera is 
solely due to anti-LPS antibody; however, a 
strong epidemiological correlation has been found 
between them in the field (Mosley et a!, 1968). 
Since Pasteur vaccine is safe and easily administered, 
this may offer an alternative tool for preventing 
cholera and justifying examination in a challenge 
study. 
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Table I 
Antibody responses after three oral doses of Pasteur vaccine (n = 19). 
Antibody assay 
Baseline titer Peak titer 
G M T  (range) G M T  (range) 









Rise of antibody responses after three oral doses of Pasteur vaccine ( N =  19). 
Type of 
antibodies 
No. (%) with No. (%) with 








In jejunal fluid 
slgA anti-LPS 
Any responses of the above 
Table 3 
Comparison of serum vibriocidal antibody responses after three doses of Pasteur vaccine or killed whole 
cell-B subunit vaccine. 
Vaccine 
Percent of volunteers with fold rise 
No. of lnaba Ogawa 
volunteers 
2 4  - > 8  2 16 - > 4  - > 8  1 I 6  
Pasteur 19 42 2 1 5 2 1 11 0 
WC ( 1  x l o 1 ' )  12 33 8 0 42 17 17 
+ I mg B-subunit 
WC ( 2 x  10") I I 36 9 0 9 1 64 18 
+ 5 mg B-subunit 
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